Previous 10 | Next 10 |
The rush to business maturity for the psychedelics industry has led to inevitable comparisons to the growth and development of the cannabis industry. Both have captured the interest of angel investors channeling millions of dollars into them. There are currently 60 publicly tr...
On December 20, 2021, breakthrough research at the Usona Institute , a 501(c)(3) non-profit medical research organization based in Madison, Wisconsin, revealed the true crystal forms of pharmaceutical psilocybin. It’s a new discovery of characteristics of the poly...
LONDON, Jan. 10, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that management will participate in a fireside chat at the H.C. Wainwright BioC...
At the start of last year, only a few psychedelic companies were trading on the exchange markets , with Compass Pathways (NASDAQ: CMPS) and Mind Medicine (NASDAQ: MNMD) (NEO: MMED) (“MindMed”) among them. However, this year saw a number of IPOs, which increased the to...
Study demonstrates feasibility of simultaneous administration of COMP360 psilocybin in a controlled setting to healthy participants with 1:1 therapist support London, UK – 4 January 2022 COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS”), a mental hea...
Intercontinental Exchange will add 138 securities to the ICE Biotechnology index and delete 26 as part of the annual reconstitution, effective prior to market open on December 20. Notable additions: Aurinia Pharmaceuticals (NASDAQ:AUPH), Anavex Life Sciences (NASDAQ:AVXL), Sesen Bio...
Harmony Biosciences Holdings (NASDAQ:HRMY), Aquestive Therapeutics (NASDAQ:AQST), C4 Therapeutics (NASDAQ:CCCC), Century Therapeutics (NASDAQ:IPSC), COMPASS Pathways (NASDAQ:CMPS) have been added to the Nasdaq Biotechnology Index. All the additions will be effective prior to market ...
London, U.K., Dec. 17, 2021 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today announced it has been selected for addition to the Nasdaq Biotechnology Index (Nasd...
Investors who’ve gotten on board with the AdvisorShares Psychedelics ETF (NYSEARCA:PSIL) are not hallucinating and experiencing a bad trip but rather a bad start to an exchange traded funds life. PSIL, which debuted back on Sept. 16, is down 40.6%, and the ETF has also closed nega...
“Medical treatment has made astonishing advances over the years. But the packaging and delivery of that treatment are often inefficient, ineffective, and consumer unfriendly.” That’s what Harvard researchers stated in Why Innovation in Health Care Is So Hard ...
News, Short Squeeze, Breakout and More Instantly...
2024-08-01 23:30:19 ET Image source: The Motley Fool. Compass Pathways Plc (NASDAQ: CMPS) Q2 2024 Earnings Call Aug 01, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Compass Pathways Plc (CMPS) Q2 2024 Earnings Call Tr...
Top-line COMP005 data for COMP360 phase 3 pivotal program in treatment-resistant depression expected in fourth quarter 2024 Gino Santini to join Board of Directors as Chairman Lori Englebert named new Chief Commercial Officer Cash position of $228.6 million ...
LONDON, July 24, 2024 (GLOBE NEWSWIRE) -- Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that it will release financial results for the second quarter 2024 ending June 30, 2024, a...